33765 Phase 1b randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of GLPG3667 in patients with moderate-to-severe plaque psoriasis

Abstract

Despite advances in biologic therapies for psoriasis, there remains a need for efficacious oral treatments with favorable safety profiles. Recently, small molecules targeting the JAK-STAT pathway, particularly TYK2 inhibitors, have emerged as promising new therapies. GLPG3667 is an oral potent and selective small-molecule TYK2 inhibitor in development for the treatment of inflammatory diseases. This Phase 1b randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, and efficacy of GLPG3667 (NCT04594928).